One of ASDERA's drug prevents metastases in Breast Cancer and other epithelial cancers.

Women with triple-negative breast cancer have only few toxic treatment options. The patented ASDERA approach identified the mechanism under lying "derailed" endocytosis and a drug to "rerail" it. 

The mechanism identified is up-regulation of endocytosis (of β1 interin) and the proposed drug is a derivative of HP-α-cyclodextrin to down-regulates the activity of the PI-cycle, which controls endo-cytosis.

(click on either of the icons below to download a flyer pdf (left) or a  ppt or pdf deck (right) with more details)